A 16-year-old sits rigidly on the edge of the stretcher, one knee held slightly bent beneath a school uniform. His mother says the pain began after practice, though no one saw a collision. The joint is warm and visibly fuller than the other; he watches the doorway as the nurse reaches for a blood draw. The next move has not yet been made.

— What’s your move? Read on.

Before you read
  • Which bleeding sites must be treated before confirmation?
  • When is desmopressin an option—and when is it not?

When to Think of It

Think hemophilia in a patient with a known diagnosis, family history, or unexplained deep-tissue bleeding—especially hemarthrosis, muscle hematoma, prolonged bleeding after a procedure, or intracranial symptoms after even minor trauma. Hemophilia A is factor VIII deficiency; hemophilia B is factor IX deficiency. The patient’s product, severity, inhibitor status, and written treatment plan matter.

Sick or Not Sick

The key fork is critical-site or major bleeding versus stable, noncritical bleeding. Suspected intracranial, neck/throat, gastrointestinal, retroperitoneal, or major muscle bleeding is an emergency: treat on suspicion and involve hematology immediately; do not wait for laboratory confirmation or imaging.

The First Fifteen Minutes

  • Known or suspected significant bleed: Give the patient’s prescribed factor product promptly, ideally using their individualized plan. If unavailable, for a major bleed give factor VIII 50 IU/kg IV for hemophilia A, or factor IX 100–120 IU/kg IV for hemophilia B, targeting near-normal factor activity; product recovery varies, especially for factor IX, so confirm dosing with hematology/pharmacy or institutional protocol. Factor replacement restores clot formation.
  • Mild hemophilia A with a documented prior response and noncritical bleeding: Consider desmopressin 0.3 mcg/kg IV (maximum 20 mcg) over 20–30 minutes; it releases stored factor VIII/von Willebrand factor. Do not use for hemophilia B, severe hemophilia A, or without knowing response; restrict free water and monitor sodium.
  • Mucosal bleeding as an adjunct: Consider tranexamic acid 1 g IV every 8 hours or 1–1.5 g PO three times daily, because antifibrinolysis stabilizes formed clots. Avoid for upper-tract hematuria because obstructing clots can form; check a reference/protocol for renal adjustment and duration.
  • Obtain CBC, type and screen, PT/INR, aPTT, factor activity, and inhibitor history, but do not delay factor for results when the bleed is serious. Avoid IM injections, unnecessary arterial punctures, and nonselective NSAIDs.

Definitive Care & Disposition

Consult hematology early; confirm factor level and inhibitor status, arrange repeat factor dosing and monitoring, and image the suspected site when indicated. Major or critical-site bleeds require admission—often ICU for airway, neurologic, or hemodynamic risk. A stable joint bleed may be managed with the patient’s hemophilia team and a reliable home plan after factor replacement, reassessment, and clear return precautions. In patients with inhibitors, specialist-directed bypassing therapy may be needed; emicizumab is prophylaxis, not acute bleed treatment.

How This One Kills

Waiting for imaging or coagulation results before giving factor in a suspected intracranial or airway bleed can turn a preventable bleed into irreversible neurologic injury or airway loss.
The Differential — What Else Looks Like This
  • Septic arthritis — fever, marked pain with passive motion, or systemic illness raises concern; mistaking it for hemarthrosis can delay joint-saving antibiotics and drainage.
  • von Willebrand disease — mucocutaneous bleeding and abnormal von Willebrand testing point away from isolated factor VIII/IX deficiency; the wrong replacement strategy may fail.
  • Acquired factor VIII inhibitor — new spontaneous soft-tissue bleeding and isolated prolonged aPTT in someone without a bleeding history; treating as inherited disease can delay inhibitor-directed care.

The Second-Day Story

In an older adult with no personal or family bleeding history, new extensive bruising, muscle hematomas, or post-procedural bleeding may reflect an acquired factor inhibitor rather than inherited hemophilia. In a patient already receiving prophylaxis, a bleed may be subtle and routine aPTT may be misleading, particularly with emicizumab. Let the bleeding pattern, medication/product history, factor assay, and hematology input guide the next step.
Back to Our Patient
Back to our patient: the 16-year-old with the warm, swollen knee has known severe hemophilia A and a painful atraumatic hemarthrosis, with stable vital signs and no head injury or other bleeding. Recognize the likely joint bleed, then risk-stratify: this is urgent but not currently a critical-site bleed. Check his treatment plan and inhibitor history, give prescribed factor VIII promptly (or 25–50 IU/kg IV if the plan is unavailable, with hematology/pharmacy guidance), reassess pain and joint findings, and avoid unnecessary invasive procedures. After hematology coordination and a reliable replacement/follow-up plan, disposition depends on response and the ability to manage safely at home.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 16-year-old with severe hemophilia A presenting with atraumatic right-knee pain and swelling. It began after soccer practice, but neither he nor his mother reports a collision or fall. He is afebrile and hemodynamically stable, with no head strike, other bleeding, or neurologic symptoms. The right knee is warm and fuller than the left, with painful flexion but intact distal perfusion and sensation. This is most consistent with acute hemarthrosis without current evidence of a critical-site bleed. I’m checking his factor plan and inhibitor history, giving his prescribed factor VIII now, and contacting hematology. I’ll reassess the joint and disposition him only after he has an adequate home-treatment and follow-up plan.”

Study Directive

  • From memory, distinguish hemophilia A from B and list the bleeding patterns that demand immediate factor replacement.
  • Work three factor-dose calculations: one joint bleed, one critical-site bleed, and one case with a product-specific recovery caveat.
  • Review your institution’s pathway for hemophilia with inhibitors and identify how emicizumab affects coagulation testing.

Recent Literature